Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, shared a post on X:
“ESTRO26 – Ricardo Umberto e2irradiate EORTC prospective OLIGOCARE registry of SABR for oligomets. ~2500 patients, ~3500 mets.
- Local failure 5% at 1 year and 11% at 3 years
- Colorectal cancer has higher risk of progression
- Minimum PTV dose correlated with outcome
We should aim to deliver high quality SABR to optimise control!”
To which Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, added:
“Largest prospective SBRT registry in the world!”
Other articles featuring Shankar Siva and Drew Moghanaki on OncoDaily.
